Other substances

Amprenavir

An HIV protease inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
7
 AI-suggested references
0
 Clinical trials

General information

Amprenavir on PubChem

Marketed as

AGEMERASE; PROZEI

 

Structure image - Amprenavir

CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N

Supporting references

Link Tested on Impact factor Notes Publication date
In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex
Spike protein ACE2 Small molecule In silico 		in silico

Predicted to destabilize the SARS-CoV-2 Spike-host's ACE2 receptor interface.

 Dec/28/2020

AI-suggested references

Link Publication date
Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 through a Molecular Docking Study.
Mar/01/2022
Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins.
Aug/04/2021
Identification of potential antivirals against SARS-CoV-2 using virtual screening method.
Feb/10/2021
Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
Oct/02/2021
In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs
Mar/29/2022
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.
Sep/21/2020
Destabilizing the structural integrity of COVID-19 by caulerpin and its derivatives along with some antiviral drugs: An in silico approaches for a combination therapy.
Jul/23/2020
Export (.csv)